Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5844287 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2016 | 6 Pages |
Abstract
Methamphetamine is a psychostimulant that was initially synthesized in 1920. Since then it has been used to treat attention deficit hyperactive disorder (ADHD), obesity and narcolepsy. However, methamphetamine has also become a major drug of abuse worldwide. Under conditions of abuse, which involve the administration of high repetitive doses, methamphetamine can produce considerable neurotoxic effects. However, recent evidence from our laboratory indicates that low doses of methamphetamine can produce robust neuroprotection when administered within 12Â h after severe traumatic brain injury (TBI) in rodents. Thus, it appears that methamphetamine under certain circumstances and correct dosing can produce a neuroprotective effect. This review addresses the neuroprotective potential of methamphetamine and focuses on the potential beneficial application for TBI.
Keywords
AMPAUTDFDATBIUSPnorepinephrine transporterVMATN-methyl-d-aspartateNMDAOGDDATCSSSSTBcl-2NATPI3KBDNFTraumatic brain injuryAktα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acidMRIDopamine transporterUnited States PharmacopeiaADHDMagnetic resonance imagingPositron emission tomographyVesicular monoamine transporterIntravenousUntreatedFood and Drug AdministrationSERTserotonin transporterSomatostatinStrokebrain derived neurotrophic factorB-cell lymphoma 2MethamphetamineOxygen glucose deprivationParvalbuminPETprotein kinase B
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Thomas Rau, John Ziemniak, David Poulsen,